New Insights on Alzheimer’s Treatment

Researchers in Japan believe that an existing drug might serve as a new treatment for Alzheimer’s disease. They conducted a series of experiments involving an amino acid known as arginine, which is currently prescribed for high blood pressure. Interestingly, this treatment seemed to help reduce the accumulation of a protein that is associated with Alzheimer’s in mice, as reported in a recent study published in the journal Neurochemistry International.

Yoshitaka Nagai, a neuroscientist at Kindai University and coauthor of the study, mentioned, “Our study demonstrates that arginine can suppress amyloid-beta aggregation both in vitro and in vivo.” He explained that it’s exciting because arginine has a known safety profile and is inexpensive, which could make it a viable candidate for repurposing as a treatment option for Alzheimer’s.

While the exact causes of Alzheimer’s are still unclear, amyloid-beta proteins play a significant role in this complex picture. These proteins, while part of normal brain function, can become sticky and form plaques. These plaques are considered a defining characteristic of Alzheimer’s, although not every patient displays them.

The researchers found that arginine could help break down these plaques. They observed this by providing the mice, which had amyloid-beta buildup, with drinking water and food infused with the amino acid. Remarkably, the mice that received arginine not only showed reduced plaque buildup but also appeared to perform better cognitively and behaviorally. This was tested by placing them in an elevated Y-shaped maze, where their movement and tendency to enter the ‘open arms’—a sign of healthy mice avoiding open spaces—were measured.

Clinical trials in humans are yet to be completed to confirm these results, but the researchers are hopeful about its potential. “Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders,” Nagai said.

Other studies have also explored innovative methods for treating Alzheimer’s. For instance, scientists in China reported that they managed to reverse the disease’s progression almost immediately using nanoparticles injected into the brain. Meanwhile, another Japanese team demonstrated the effectiveness of synthetic peptides to halt the disease in its early stages.

Despite these advances, the broader role of amyloid-beta in brain function is still not fully understood. So, the conversation about whether targeting these proteins might lead to meaningful treatments—or a potential cure—continues.

More on Alzheimer’s: Lab Mice Exposed to Microplastics Show Signs of Dementia